Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Waldschmidt, D. [1 ]
El-Khoueir, A. B. [2 ]
Kim, R. D. [3 ]
Harris, W. P. [4 ]
Sung, M. W. [5 ]
Iqbal, S. [2 ]
Zhang, A. [6 ]
Nakajima, K. [6 ]
Galle, P. R. [7 ]
机构：
[1] Univ Klin Koln, Klin Gastroenterol & Hepatol, Cologne, Germany
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[5] Tisch Canc Inst Mt Sinai, New York, NY USA
[6] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[7] Univ Med Ctr Mainz, Mainz, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
153
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [1] Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    El-Khoueiry, Anthony B.
    Kim, Richard D.
    Harris, William P.
    Sung, Max W.
    Waldschmidt, Dirk
    Iqbal, Syma
    Zhang, Xiaojing
    Nakajima, Keiko
    Galle, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [2] Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    Galle, P. R.
    Kim, R. D.
    Sung, M. W.
    Harris, W. P.
    Waldschmidt, D.
    Cabrera, R.
    Mueller, U.
    Nakajima, K.
    Ishida, T.
    El-Khoueiry, A. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S691 - S692
  • [3] Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).
    Kim, Richard D.
    Harris, William P.
    Sung, Max W.
    Waldschmidt, Dirk Thomas
    Cabrera, Roniel
    Mueller, Udo
    Menezes, Flavia
    Ishida, Tatiane
    Galle, Peter R.
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [4] Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).
    El-Khoueiry, Anthony B.
    Kim, Richard D.
    Harris, William Proctor
    Sung, Max W.
    Waldschmidt, Dirk
    Cabrera, Roniel
    Garosi, Vittorio Luigi
    Zebger-Gong, Hong
    Brennan, Barbara J.
    Wang, Ying A.
    Mueller, Udo
    Ishida, Tatiane Cristine
    Galle, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
    Llovet, Josep M.
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Finn, Richard S.
    Galle, Peter R.
    Kaneko, Shuichi
    Meyer, Tim
    Qin, Shukui
    Dutcus, Corina E.
    Chen, Erluo
    Dubrovsky, Leonid
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)
    Chuang, Chienhuai
    Liu, Tsung-Hao
    Hsu, Meng-Chi
    Chang, Mo-Jung
    Cheng, Ann-Lii
    Hsu, Chiun
    ANNALS OF ONCOLOGY, 2023, 34 : S1398 - S1398
  • [7] Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
    van Laethem, J-L.
    Borbath, I.
    Karwal, M.
    Verslype, C.
    Van Vlierberghe, H.
    Kardosh, A.
    Zagonel, V.
    Stal, P.
    Sarker, D.
    Palmer, D.
    Vogel, A.
    Edeline, J.
    Cattan, S.
    Kudo, M.
    Cheng, A-L.
    Ogasawara, S.
    Siegel, A. B.
    Chisamore, M.
    Wang, A.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S819 - S819
  • [8] Phase II study of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC)
    Hsiehchen, D.
    Kainthla, R.
    Zhu, H.
    Jones, A.
    Beg, M. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S822 - S823
  • [9] Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom M.
    Trojan, Jorg
    Cebon, Jonathan S.
    Liem, Andre K. D.
    Lipton, Lara Rachel
    Gupta, Charu
    Wu, Benjamin
    Litten, Jason B.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [10] Trial in progress: phase 1b dose-finding study of axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma (RCC)
    Choueiri, T. K.
    Plimack, E. R.
    Gupta, S.
    Cho, D.
    Hutson, T. E.
    Puzanov, I.
    George, S.
    Olencki, T.
    Vaishampayan, U.
    Chakrabarti, D.
    Pithavala, Y. K.
    Williams, J. A.
    Rosbrook, B.
    Tarazi, J. C.
    Atkins, M. B.
    BJU INTERNATIONAL, 2014, 114 : 4 - 5
12345